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Introduction: Guidelines caution prescribers and patients against 
chronic benzodiazepine use (BZD). Nevertheless, BZD use among 
nursing home residents remains high. We focused on individual resi-
dents and explored benefit and harm of chronic BZD use, willingness 
to try, and barriers against the discontinuation of chronic BZD use by 
questioning the general practitioner (GP) and the nurse.
Patients (or Materials) and Methods: In this cross-sectional study, 
we selected nursing home residents with at least 3 months of BZD 
use. A resident-specific questionnaire was addressed to the GP and 
nurse. For every resident, the GP and nurse had to score 8 barrier 
statements on a 10 point Likert scale. Additionally, we collected 10 
general attitudes scored by GPs and nurses. The questionnaire was 
based on an expert meeting and was pretested.
Results: We received data for 109 chronic BZD users. GPs and nurses 
indicated that the BZD still had the desired effect in, respectively, 
87% and 83% of the residents, and that except for dependence; 
there were no observed side effects in 75% and 70% of the residents. 
Overall, GPs had higher barriers than the nurses. Nevertheless, the 
willingness to stop among GPs was higher (respectively 33% vs. 
21%). Both caregivers were willing to stop in 13% of the residents. 
The most common barriers against discontinuation was for both 
caregivers the fear that initial problems will come back and the pref-
erence of a pharmacologic treatment instead of a nonpharmacologic 
treatment. The GPs perceived the resident’s motivation as a larger 
barrier than the nurses (median, 9 vs 7; P = 0.001) and indicated 
more often that discontinuation of BZDs can lead to an increase in 
care burden (median, 8 vs 6; P = 0.028). Of all 10 general statements, 
the most common attitude among both GPs and nurses was that the 
longer the resident takes the medication, the more difficult it is to stop 
(median, 8), and the resident’s old age makes it difficult and unneces-
sary to stop. Nurses, in contrast to the GPs, indicated that there is 
little knowledge on alternative strategies to handle troubles when 
stopping BZDs (median, 7 vs 2; P < 0.001) and little scientific infor-
mation available for stopping (median, 6 vs 2; P = 0.004). The scores 
for resident-specific barriers were higher than for general statements.
Conclusion: The perceived effectiveness, the absence of side effects 
and the presence of dependence in most residents that use BZD 
chronically, result in a low willingness to stop. Implementation of 
discontinuation initiatives have to address different barriers of differ-
ent parties requiring multidisciplinary evaluation of residents.
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Introduction: The ICH E7 guideline for studies involving geriatric 
patients intends to improve the knowledge about medicines in that 
population. As a legislative document, it might not reflect the needs 
of health care professionals. This study investigated what information 
health care professionals, regulatory agencies, and pharmaceutical 
industries actually consider necessary for rational drug prescribing 
to older individuals.
Patients (or Materials) and Methods: A 29-item questionnaire was 
composed, focusing on the representation of older individuals in tri-
als, the pharmacokinetics, efficacy and safety, and the convenience of 
use of medicinal products. Forty-three European physicians, pharma-
cists, ethicists, regulators, and professionals from the pharmaceuti-
cal industry, all specialized in medication for older individuals were 
included. A second questionnaire was composed of 11 control items 
and 5 new items, based on comments. Median scores, differences 
between clinical and nonclinical respondents, and the consistency of 
responses were analyzed.
Results: Thirty-seven (86%) respondents returned the initial ques-
tionnaire: 23 clinicians and 14 nonclinical professionals. The second 
was returned by 21 clinicians and 10 nonclinical professionals (31/37 
[84%]). There were no significant differences between respondents 
regarding 10 control items. Information about 32 (94%) of the 34 
items was considered necessary. Information about age-related dif-
ferences in adverse events, locomotor effects, drug–disease interac-
tions, dosing instructions, and information about the proportion of 
included 65+ patients was considered necessary by most respondents. 
The clinicians considered information significantly more important 
than did the nonclinical respondents about the inclusion of 75+, time 
until benefit in older people, anticholinergic effects, drug–disease 
interactions, and the convenience of use.
Conclusion: This study reveals that items considered necessary are 
currently not included in the ICH E7 guideline or its supplement, 
the Q&A document; namely, information about effects on the loco-
motor system, drug–disease interactions, and dosing instructions. 
Also, clinicians’ and nonclinicians’ opinions differed significantly in 
15% of the items. Therefore, all stakeholders should collaborate to 
improve the availability of information for the rational prescribing 
of medicines to older individuals.
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Introduction: Health care professionals in daily practice use national 
handbooks for rational prescribing of medicines to older patients. 
The study objective was to investigate the availability and clinical 
applicability of such information in European and American hand-
books.
Patients (or Materials) and Methods: The Belgian Repertorium, 
German Rote Liste, British National Formulary (BNF), Dutch 
Farmacotherapeutisch Kompas (FK), and American Physician’s Desk 
Reference (Concise Monograph and Product Label [PL]) were ana-
lyzed. All 35 nongeneric medicines for diseases frequently present 
in older people with a first European centralized approval between 
2008 and 2011 and an FDA approval before October 2012 were 
included. A 19-item checklist, based on the ICH-E7 criteria, was used 
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to study the availability of information about the studied popula-
tion, clinical experience, pharmacokinetic properties, and drug–drug 
interactions. Using the Systematic Information for Monitoring score, 
available information was considered clinically applicable if it pro-
vided information that could be applied in clinical practice. Missing 
information was either a statement that information was absent, 
unjustifiably nonavailable information, or hollow statements (eg, 
“caution in older patients”). Descriptive statistics (frequencies) were 
applied using SPSS 20.0.
Results: The availability of relevant and clinically applicable infor-
mation ranged between 10% (Belgian Repertorium and BNF) and 
20% (FK), except for the PL (mean, 66%). The PL, which is compa-
rable to the European SmPC, appeared a more extensive document 
(7–32 pages) than the other handbooks (2 pages). In the handbooks, 
most information was present about drug–drug interactions (range, 
30%–75%). Information about patient characteristics and about 
experience in older people was present in < 7% of the handbook 
texts, except for the PL (48% and 81%, respectively). Clinically 
applicable information (what to monitor, critical value, how to 
respond) concerning renal impairment ranged from 4% to 29%.
Conclusion: This study found that the availability and clinical appli-
cability of information about older people for rational prescribing of 
medicines is incomplete in the investigated European and American 
handbooks. Because these handbooks are the primary documents 
that guide prescribing in actual medical practice, the availability and 
clinical applicability of the information on older individuals should 
be improved.
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Introduction: The aim of this study was to investigate the effect of 
chronic pravastatin treatment on diminished corpus cavernosum 
(CC) function associated with aging.
Patients (or Materials) and Methods: Male rats were divided into 3 
groups as young rats (12–14 weeks old), aged rats (72–80 weeks old), 
and aged rats given 10 mg/kg/d of pravastatin in drinking water for 
6 weeks. Systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were monitored by tail-cuff method. Total cholesterol, LDL-
cholesterol, HDL-cholesterol, triglycerides, and testosterone levels 
were estimated in blood. NO-mediated endothelium-dependent and 
neurogenic CC relaxation were evaluated by acetylcholine (ACh, 
0.1 nM–100 µM), and electrical field stimulation (EFS, 30 V, 5 ms, 
2–32 Hz), respectively. Changes in protein expression levels of eNOS, 
p-eNOS, and nNOS were assessed by immunohistochemistry.
Results: In aged rats, NO-mediated both endothelium-dependent 
and neurogenic CC relaxation was significantly impaired as com-
pared with young rats. Besides, eNOS and nNOS expressions 
decreased significantly in CC from aged rats compared with those 
from young rats. The diminished relaxation in response to ACh or 
EFS as well as reduced expressions of eNOS, p-eNOS and nNOS 
in CC of aged rats were improved by pravastatin treatment. SBP, 
DBP, and plasma levels of total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, and testosterone did not change with aging 
or pravastatin treatment.
Conclusion: The present results suggest that chronic pravastatin 
treatment enhances NOS activity and NO-mediated relaxations in 
the rat CC, and this effect does not seem to be associated with lipid-
lowering effect of this drug.
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Introduction: Adverse drug reactions (ADR) in children are an 
important medical problem. The ADRs in pediatrics are not the same 
in adults. Our aim was to define such specifity for periods of child-
hood and to compare found results with ones of adults.
Patients (or Materials) and Methods: ARCADe (Adverse Reactions 
in Crimea Autonomy DatabasE) was used for search of ADRs and 
their analysis. Classification of age stages of American Academy 
of Pediatrics was used. It defines babies (0–1 y.o.), toddlers (1–3), 
preschool (3–5), and grade-school (5–12) periods of childhood, 
and teenagers (12–18). The pharmaceutical groups and drugs were 
determined using WHO ATC index. WHO classes and Naranjo 
algorithm was used in causality and FDA criteria in seriousness 
assessment.
Results: The total amount of ARCADe records in 2011–2012 
period is 2528. Amount of ADR reports for pediatric groups: 
babies, 187 (7.4%); toddlers, 138 (5.5%); preschool, 52 (2%); 
grade-school, 100 (4%); and teenagers, 52 (2%). Other reports 
were about reactions in adult patients (n = 1999, 79%). The 
amount of reports informing about ADR in male decreases with 
age. In babies, toddlers, and preschool children, ADRs in males are 
more often (55%–60%); in schoolchildren and teenagers, the ratio 
for males and females is 1:1, in adults ADRs in females are more 
frequent (60%). The most frequent clinical presentation of ADR 
in all groups is skin rash with different severity (including Lyell’s 
syndrome). In babies, rashes were found in 89.3% of cases; in tod-
dlers, in 77.5%; in preschool and grade-school children, in 75% 
and in 56%; and in teenagers, in 63.5% In adults, the frequency of 
rashes was lower (42%). The incidence of fever varied from 3.2% 
in babies to 11.4% in preschool children; then in teenagers and 
adults it decreases to 3.8% to 4%. The seriousness of ADRs was 
maximal in toddlers (75%), less in babies (71.7%); in other groups 
it was equal to adult rates (66%). The products caused ADRs most 
frequently in pediatric groups as well as in adults were antibacterial 
drugs. For them there was trend to decrease from babies (56.1%) 
to adults (36.7%) while in teenagers and adult patients the leader 
drug from this group was ceftriaxone (13.5% and 4.7%); in babies 
and toddlers ADR was mostly caused by ceftazidime (21.9% and 
12.3%). In preschool children, the leader was ibuprofen (7.7%) 
